How to Reconstitute CJC-1295: Storage Stability After Mixing

What Is CJC-1295 and Why Does Reconstitution Technique Matter?

CJC-1295 is a synthetic 30-amino-acid GHRH analog with a Drug Affinity Complex (DAC) modification that covalently binds to albumin after injection, extending the plasma half-life from minutes to approximately 6 to 8 days. Teichman et al. (2006) confirmed this prolonged half-life in a Phase 1 dose-escalation trial (N=65), reporting sustained growth hormone (GH) and IGF-1 elevation for up to 14 days after a single dose. That pharmacokinetic advantage disappears if the peptide is degraded before it ever reaches the body.

Reconstitution errors are the single most preventable source of peptide degradation. Shaking a vial introduces mechanical shear that fragments peptide bonds. Adding diluent directly onto the lyophilized cake causes local pH spikes that accelerate hydrolysis. Getting these steps right protects both potency and patient safety.

The Chemistry Behind Lyophilized Peptide Stability

Lyophilized (freeze-dried) peptides are stable because removing water slows hydrolysis, oxidation, and aggregation to near-zero rates. Wang (1999) established that peptide degradation in the solid state follows Arrhenius kinetics and that residual moisture content below 1% is the primary determinant of long-term shelf life. CJC-1295 vials stored at -20 °C with intact seals maintain potency for 12 to 24 months under these conditions.

Once water is reintroduced, that protection ends. The reconstituted peptide is now subject to hydrolysis, aggregation, and microbial growth. Every decision made during reconstitution directly affects how quickly those degradation pathways proceed.

Bacteriostatic vs. Sterile Water: Why It Matters

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative. That preservative suppresses microbial growth in a multi-dose vial across repeated needle punctures. Sterile water for injection (SWFI) contains no preservative at all. According to USP Chapter 797 compounding standards, a preserved multi-dose preparation stored at 2 to 8 °C carries a beyond-use date (BUD) of up to 28 days, while an unpreserved preparation must be discarded within 12 hours at room temperature or 24 hours refrigerated. Choosing BWFI over SWFI is not a preference. It is a stability requirement for any multi-dose reconstituted peptide.

Step-by-Step Reconstitution Protocol

The full procedure takes under five minutes and requires sterile technique throughout. Gather supplies before opening anything.

Supplies Checklist

You need the CJC-1295 lyophilized vial, a vial of bacteriostatic water for injection, two alcohol swabs (70% isopropyl), a 1 mL or 3 mL Luer-lock syringe with a 23 to 25 gauge needle for drawing up diluent, and a U-100 insulin syringe for dosing. Gloves are recommended. Work on a clean, non-porous surface. CDC injection safety guidelines require a new, sterile needle and syringe for every vial entry.

Reconstitution Steps

1. Wash hands for at least 20 seconds.
2. Swab the rubber stopper of both vials with separate alcohol swabs. Allow 30 seconds of air-dry time. Do not blow on or fan the stopper.
3. Draw up the desired volume of bacteriostatic water (see the dosing calculator section below) into the syringe.
4. Insert the needle into the CJC-1295 vial at a 45-degree angle. Aim the needle tip at the glass wall, not the powder cake.
5. Depress the plunger slowly, letting the water run down the inner wall of the vial. This prevents direct impaction on the lyophilized cake and the pH disruption that follows.
6. Withdraw the needle. Do not shake. Swirl gently for 15 to 30 seconds or allow the vial to sit at room temperature for 2 to 3 minutes until the powder dissolves completely. The solution should be clear and colorless. Discard immediately if cloudy, particulate, or discolored. FDA guidance on injectable drug product visual inspection classifies visible particles as a critical defect.
7. Label the vial with the date and time of reconstitution.
8. Refrigerate at 2 to 8 °C within 15 minutes.

How Much Bacteriostatic Water to Use: The Dosing Calculator

The volume of bacteriostatic water determines the concentration of the final solution, which determines how many units on an insulin syringe correspond to a given dose. Getting this math right prevents accidental overdosing.

Concentration Formula

The formula is straightforward:

Concentration (mcg/mL) = Total peptide in vial (mcg) / Volume of diluent added (mL)

For a standard 2 mg (2,000 mcg) CJC-1295 vial:

| Diluent Added | Concentration | 1,000 mcg dose = | 500 mcg dose = | |---|---|---|---| | 1 mL | 2,000 mcg/mL | 0.50 mL (50 units) | 0.25 mL (25 units) | | 2 mL | 1,000 mcg/mL | 1.00 mL (100 units) | 0.50 mL (50 units) | | 2.5 mL | 800 mcg/mL | 1.25 mL (125 units) | 0.63 mL (63 units) |

Adding 2 mL gives the cleanest math on a U-100 syringe and keeps injection volumes in the subcutaneous sweet spot of 0.5 to 1.0 mL per site. Heise et al. (2014) confirmed that subcutaneous depot volume affects absorption rate and local tolerability, with volumes above 1 mL per site producing more injection-site reactions.

Reading a U-100 Insulin Syringe

A U-100 syringe holds 100 units, which equals exactly 1 mL. Each unit equals 0.01 mL. At a concentration of 1,000 mcg/mL (2 mg vial reconstituted in 2 mL), each unit on the syringe equals 10 mcg of CJC-1295. A 500 mcg dose equals 50 units. A 1,000 mcg dose equals 100 units (a full 1 mL syringe).

Always draw up the dose, then tap the syringe barrel and expel air bubbles before injecting. Air bubbles do not harm the peptide, but they displace volume and reduce dose accuracy.

CJC-1295 Storage Stability After Mixing: The Evidence

This is the section that matters most to patients asking the primary question. Post-reconstitution stability is governed by three variables: temperature, light exposure, and preservative presence.

Refrigerated Stability (2 to 8 °C)

With bacteriostatic water as the diluent, reconstituted CJC-1295 stored at 2 to 8 °C in the original sealed vial should remain stable for up to 28 days. This is the industry-standard BUD assigned by compounding pharmacies operating under USP 797. The 28-day figure is not arbitrary. Bhambhani and Bhatt (2010) reviewed peptide formulation stability and identified temperature, pH, and preservative identity as the three primary determinants, finding benzyl alcohol effective against the most common contaminant organisms encountered in multi-dose vials. Stability data for CJC-1295 specifically are limited in peer-reviewed literature, because the compound is not FDA-approved. Extrapolating from published GHRH analog stability data is the accepted pharmacist approach in compounding practice.

Room Temperature Stability

Do not store reconstituted CJC-1295 at room temperature (15 to 25 °C) for extended periods. Peptide hydrolysis rates approximately double with every 10 °C increase in temperature, following the Arrhenius relationship described by Wang (1999). A vial left on a countertop loses meaningful potency within 24 to 48 hours even with benzyl alcohol preservative present. If you accidentally leave the vial at room temperature for less than 4 hours, refrigerate it immediately and continue use. Beyond 8 hours at room temperature, discard and reconstitute a fresh vial.

Freeze-Thaw Cycles After Reconstitution

Do not freeze a reconstituted peptide solution. Carpenter and Chang (1996) demonstrated that ice crystal formation during freezing shears peptide bonds and promotes aggregation in solution, even at low peptide concentrations. Reconstituted solutions are not suitable for re-freezing. The lyophilized powder is designed for long-term frozen storage. Once reconstituted, commit to the 2 to 8 °C refrigerated storage protocol.

Light and Container Considerations

UV exposure accelerates oxidation of susceptible amino acid residues, particularly tryptophan, methionine, and cysteine. Kerwin and Remmele (2007) found that even ambient fluorescent light exposure over 24 hours produced measurable oxidative degradation in peptide solutions stored in clear glass vials. Keep the reconstituted vial in its original amber-glass or foil-wrapped vial. If the vial is clear glass, store it inside an opaque container or the original box in the refrigerator.

Injection Technique for Subcutaneous Administration

CJC-1295 is administered subcutaneously, not intramuscularly. The DAC modification produces its sustained-release pharmacology precisely because it binds to albumin in the interstitial fluid and bloodstream after subcutaneous absorption.

Site Selection and Rotation

Preferred injection sites are the lower abdomen (at least 2 inches from the navel), the lateral thigh, and the dorsolateral arm. Rotate sites with every injection to prevent lipoatrophy and nodule formation. Frid et al. (2016) documented that consistent rotation across at least four quadrants in the same region reduces subcutaneous tissue damage compared to single-site repeated injection.

Injection Angle and Depth

Use a 45-degree angle with a 6 mm or 8 mm needle on the insulin syringe for most adults. Lean adults (body fat below 15%) may inject at 45 degrees while pinching a skin fold. Patients with higher body fat percentages can inject at 90 degrees without pinching. Hirsch et al. (2014) confirmed in a review of insulin injection technique that 4 to 8 mm needle lengths are sufficient for reliable subcutaneous delivery in most adults, without reaching the intramuscular layer.

Timing Relative to Meals and Sleep

CJC-1295 stimulates GH pulsatility, which naturally peaks during slow-wave sleep. Van Cauter et al. (2000) showed that approximately 70% of total daily GH secretion occurs during the first few hours of sleep. Administering CJC-1295 30 to 60 minutes before bed, in a fasted state, may align the pharmacodynamic window with the endogenous sleep-associated GH pulse. Avoid administration within 2 hours of a high-carbohydrate meal, as postprandial hyperinsulinemia suppresses GH release via hypothalamic somatostatin, potentially blunting the peptide's effect.

Clinical Evidence for CJC-1295 Efficacy

The published human trial data are limited but provide a foundation for dosing parameters.

Phase 1 Dose-Escalation Data

Teichman et al. (2006) conducted a randomized, placebo-controlled Phase 1 trial (N=65 healthy adults) testing single and multiple doses of CJC-1295 (30, 60, 125, and 250 mcg/kg subcutaneously). At 60 mcg/kg, mean GH area under the curve increased 2- to 10-fold above baseline. Mean IGF-1 levels rose by 20 to 30% above baseline within 7 days and remained elevated for up to 28 days after a single dose. The authors noted that the authors stated: "CJC-1295 was well tolerated at all doses tested, with dose-dependent increases in mean plasma GH and IGF-1 concentrations that were sustained over prolonged periods." Adverse events were mild and included transient flushing, headache, and injection-site discomfort.

IGF-1 as a Monitoring Biomarker

Because CJC-1295 acts upstream via GHRH receptor agonism rather than directly supplying exogenous GH, the pituitary still regulates GH pulse amplitude through normal feedback. Ho et al. (1988) established that IGF-1 is the most reliable surrogate marker for integrated GH secretion over 24 hours, correlating with r=0.82 to 24-hour GH area under the curve. Monitoring serum IGF-1 every 8 to 12 weeks during CJC-1295 use allows dose titration and early detection of IGF-1 excess. Target range for most age groups is the upper quartile of age-adjusted reference ranges, not supraphysiologic levels.

Compounding Pharmacy Quality and Regulatory Context

CJC-1295 is not FDA-approved as a drug product. It is available only through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. FDA guidance on compounded drug products requires that compounded preparations use pharmaceutical-grade active pharmaceutical ingredients (APIs) meeting USP standards, and that pharmacies maintain sterility testing, potency testing, and appropriate BUD labeling.

A critical quality checkpoint when sourcing compounded CJC-1295 is requesting the Certificate of Analysis (CoA) from the compounding pharmacy. A legitimate CoA will show HPLC purity (look for >98% purity), endotoxin testing results (acceptable limit: <5 EU/kg/dose per FDA guidance on pyrogens), sterility test results, and peptide identity confirmation by mass spectrometry. Gudeman et al. (2013) documented serious patient harm from contaminated compounded injectables, underscoring that CoA review is not optional due diligence. It is a basic safety step.

Recognizing Degraded Peptide: When to Discard

Reconstituted CJC-1295 should be clear and colorless. Any of the following changes signal degradation and require immediate discard:

• Cloudiness or turbidity. Indicates aggregation or microbial contamination. Mahler et al. (2009) showed that visible aggregation in peptide solutions corresponds to greater than 1 micrometer particle formation, which poses an embolic risk on injection.
• Yellow or brown discoloration. Indicates oxidative degradation of aromatic residues.
• Visible particulates. Classified as a critical defect per FDA visual inspection guidance.
• Unusual odor. May indicate microbial growth despite preservative.
• Beyond 28 days from reconstitution date. Discard regardless of appearance.

Never inject a solution that fails any of the above checks. Reconstitute a fresh vial.

Contraindications and Safety Considerations

CJC-1295 is contraindicated in active malignancy. GH and IGF-1 have well-established mitogenic effects, and Renehan et al. (2004) in a meta-analysis of 16 prospective studies found that a 1 standard deviation increase in serum IGF-1 was associated with a relative risk of 1.49 (95% CI 1.14 to 1.95) for colorectal cancer and 1.65 (95% CI 1.26 to 2.16) for premenopausal breast cancer. This does not imply CJC-1295 causes cancer at physiologic IGF-1 levels, but it does mean active malignancy is an absolute contraindication.

Additional contraindications include:

• Pregnancy and lactation (no safety data; FDA pregnancy category considerations require demonstrated safety)
• Uncontrolled diabetes mellitus (GH is counter-regulatory to insulin; Moller and Jorgensen (2009) showed GH excess increases hepatic glucose output and reduces peripheral insulin sensitivity)
• Intracranial hypertension history
• Benzyl alcohol allergy (use SWFI with a 24-hour BUD if confirmed allergy, and use only single-dose vials)
• Age <18 (open epiphyseal plates; supraphysiologic GH stimulation risks premature closure per Giustina et al. (2008))

Monitoring Protocol During CJC-1295 Use

Order baseline labs before starting. Recheck at 8 weeks and again at 16 weeks.

| Lab | Baseline | 8 Weeks | 16 Weeks | |---|---|---|---| | Serum IGF-1 | Yes | Yes | Yes | | Fasting glucose | Yes | Yes | Yes | | HbA1c | Yes | No | Yes | | Fasting insulin | Yes | No | Yes | | Thyroid panel (TSH, free T4) | Yes | No | Yes | | CBC | Yes | No | Yes |

Clemmons (2011) recommended IGF-1 monitoring as the primary safety endpoint for any GH-axis intervention, with IGF-1 values persistently above the age-adjusted 97th percentile prompting dose reduction or cessation. The Endocrine Society guidelines on adult GH deficiency, available through academic.oup.com/jcem, define IGF-1 excess as a key dose-limiting criterion.